Sarepta Therapeutics annual stock-based compensation
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Stock-Based Compensation Growth & History (SRPT)
Sarepta Therapeutics's stock-based compensation was $123.4M for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $123.4M | −$60.9M | −33.05% |
| 2024 | 2024-12-31 | $184.3M | $1.8M | +0.98% |
| 2023 | 2023-12-31 | $182.5M | −$50.5M | −21.67% |
| 2022 | 2022-12-31 | $233.0M | $119.1M | +104.50% |
| 2021 | 2021-12-31 | $113.9M | $5.9M | +5.43% |
| 2020 | 2020-12-31 | $108.1M | $29.5M | +37.49% |
| 2019 | 2019-12-31 | $78.6M | $28.5M | +56.81% |
| 2018 | 2018-12-31 | $50.1M | $19.7M | +64.54% |
| 2017 | 2017-12-31 | $30.5M | $503,000 | +1.68% |
| 2016 | 2016-12-31 | $30.0M | −$2.2M | −6.71% |
| 2015 | 2015-12-31 | $32.1M | $11.8M | +57.86% |
| 2014 | 2014-12-31 | $20.3M | $9.2M | +82.84% |
| 2013 | 2013-12-31 | $11.1M | $8.0M | +261.50% |
| 2012 | 2012-12-31 | $3.1M | −$51,000 | −1.63% |
| 2011 | 2011-12-31 | $3.1M | −$40,000 | −1.26% |
| 2010 | 2010-12-31 | $3.2M | $795,000 | +33.49% |
| 2009 | 2009-12-31 | $2.4M | — | — |
Sarepta Therapeutics quarterly stock-based compensation
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $24.5M | −$12.6M | −33.90% |
| Q1 2026 | 2026-03-31 | $29.4M | −$12.0M | −29.04% |
| Q4 2025 | 2025-12-31 | $30.0M | −$19.7M | −39.58% |
| Q3 2025 | 2025-09-30 | $14.9M | −$28.5M | −65.65% |
| Q2 2025 | 2025-06-30 | $37.0M | −$13.5M | −26.66% |
| Q1 2025 | 2025-03-31 | $41.4M | $736,000 | +1.81% |
| Q4 2024 | 2024-12-31 | $49.7M | $3.9M | +8.40% |
| Q3 2024 | 2024-09-30 | $43.5M | −$4.6M | −9.59% |
| Q2 2024 | 2024-06-30 | $50.5M | $3.1M | +6.55% |
| Q1 2024 | 2024-03-31 | $40.7M | −$558,000 | −1.35% |
| Q4 2023 | 2023-12-31 | $45.8M | −$4.7M | −9.27% |
| Q3 2023 | 2023-09-30 | $48.1M | −$2.4M | −4.67% |
| Q2 2023 | 2023-06-30 | $47.4M | −$55.5M | −53.95% |
| Q1 2023 | 2023-03-31 | $41.3M | $12.1M | +41.28% |
| Q4 2022 | 2022-12-31 | $50.5M | $20.7M | +69.60% |
| Q3 2022 | 2022-09-30 | $50.4M | $23.7M | +88.94% |
| Q2 2022 | 2022-06-30 | $102.9M | $73.9M | +255.18% |
| Q1 2022 | 2022-03-31 | $29.2M | $690,000 | +2.42% |
| Q4 2021 | 2021-12-31 | $29.8M | $255,000 | +0.86% |
| Q3 2021 | 2021-09-30 | $26.7M | −$219,000 | −0.81% |
| Q2 2021 | 2021-06-30 | $29.0M | $1.4M | +4.90% |
| Q1 2021 | 2021-03-31 | $28.5M | $4.5M | +18.66% |
| Q4 2020 | 2020-12-31 | $29.5M | $7.5M | +33.82% |
| Q3 2020 | 2020-09-30 | $26.9M | $6.3M | +30.36% |
| Q2 2020 | 2020-06-30 | $27.6M | $7.9M | +39.74% |
| Q1 2020 | 2020-03-31 | $24.0M | $7.9M | +48.86% |
| Q4 2019 | 2019-12-31 | $22.1M | $9.2M | +71.86% |
| Q3 2019 | 2019-09-30 | $20.6M | $9.2M | +79.70% |
| Q2 2019 | 2019-06-30 | $19.8M | $4.5M | +29.34% |
| Q1 2019 | 2019-03-31 | $16.1M | $5.6M | +53.33% |
| Q4 2018 | 2018-12-31 | $12.8M | $5.5M | +74.29% |
| Q3 2018 | 2018-09-30 | $11.5M | $4.6M | +65.91% |
| Q2 2018 | 2018-06-30 | $15.3M | $4.8M | +46.00% |
| Q1 2018 | 2018-03-31 | $10.5M | $4.8M | +84.28% |
| Q4 2017 | 2017-12-31 | $7.4M | $497,000 | +7.24% |
| Q3 2017 | 2017-09-30 | $6.9M | −$2.5M | −26.58% |
| Q2 2017 | 2017-06-30 | $10.5M | $3.6M | +53.22% |
| Q1 2017 | 2017-03-31 | $5.7M | −$1.1M | −16.43% |
| Q4 2016 | 2016-12-31 | $6.9M | $521,000 | +8.21% |
| Q3 2016 | 2016-09-30 | $9.4M | $3.7M | +65.90% |
| Q2 2016 | 2016-06-30 | $6.8M | $900,000 | +15.18% |
| Q1 2016 | 2016-03-31 | $6.8M | −$7.3M | −51.72% |
| Q4 2015 | 2015-12-31 | $6.3M | $581,000 | +10.07% |
| Q3 2015 | 2015-09-30 | $5.7M | $1.0M | +22.24% |
| Q2 2015 | 2015-06-30 | $5.9M | $343,000 | +6.14% |
| Q1 2015 | 2015-03-31 | $14.2M | $9.8M | +226.02% |
| Q4 2014 | 2014-12-31 | $5.8M | $2.1M | +57.96% |
| Q3 2014 | 2014-09-30 | $4.6M | $1.2M | +33.32% |
| Q2 2014 | 2014-06-30 | $5.6M | $3.3M | +141.03% |
| Q1 2014 | 2014-03-31 | $4.3M | $2.7M | +159.84% |
| Q4 2013 | 2013-12-31 | $3.7M | $2.4M | +194.91% |
| Q3 2013 | 2013-09-30 | $3.5M | $2.8M | +403.90% |
| Q2 2013 | 2013-06-30 | $2.3M | $1.9M | +426.82% |
| Q1 2013 | 2013-03-31 | $1.7M | $963,000 | +136.02% |
| Q4 2012 | 2012-12-31 | $1.2M | $563,000 | +83.41% |
| Q3 2012 | 2012-09-30 | $692,000 | $100,000 | +16.89% |
| Q2 2012 | 2012-06-30 | $440,000 | −$277,000 | −38.63% |
| Q1 2012 | 2012-03-31 | $708,000 | −$437,000 | −38.17% |
| Q4 2011 | 2011-12-31 | $675,000 | — | — |
| Q3 2011 | 2011-09-30 | $592,000 | $83,000 | +16.31% |
| Q2 2011 | 2011-06-30 | $717,000 | — | — |
| Q1 2011 | 2011-03-31 | $1.1M | — | — |
| Q3 2010 | 2010-09-30 | $509,000 | — | — |
Sarepta Therapeutics stock-based compensation trends
Over the last five fiscal years, Sarepta Therapeutics's stock-based compensation increased from $108.1M to $123.4M, a change of $15.3M. The latest reported quarter, Q2 2026, shows $24.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...